Oba Yuji, Lone Nazir A
University of Missouri, School of Medicine, Division of Pulmonary, Critical Care and Environmental Medicine, Columbia, MO, USA.
University of Missouri, School of Medicine, Division of Pulmonary, Critical Care and Environmental Medicine, Columbia, MO, USA.
J Crit Care. 2014 Oct;29(5):706-10. doi: 10.1016/j.jcrc.2014.04.011. Epub 2014 Apr 26.
The choice of vasopressor in septic shock has been a matter of debate. The purpose of this study was to systematically review overall evidence of vasopressor and inotropic agents in septic shock using a Bayesian network meta-analysis.
Databases, including Medline, Scopus, CINAHL, and Google Scholar were searched to identify relevant studies. Eligible studies were randomized controlled trials that reported mortality rates on the use of vasopressors and inotropes in patients with septic shock. We chose to use 28-day mortality as the outcome assessment criterion.
Fourteen studies with a total of 2811 patients were included in the analysis. Norepinephrine (NE) and NE + low-dose vasopressin but not epinephrine (EPI) were associated with significantly reduced mortality compared with dopamine. (Odds ratio, 0.80 [95% credibility interval, 0.65-0.99], 0.69 [0.48-0.98], and 0.56 [0.26-1.18], respectively). The addition of an inotropic agent such as dobutamine or dopexamine did not reduce mortality compared with EPI or NE alone.
Our results support the use of NE with or without low-dose vasopressin as the first-line vasopressor therapy in septic shock. No concrete evidence exists to support the use of EPI over dopamine as the second-line agent or the addition of an inotropic agent.
脓毒性休克血管升压药的选择一直存在争议。本研究的目的是使用贝叶斯网络荟萃分析系统评价脓毒性休克中血管升压药和正性肌力药物的总体证据。
检索包括Medline、Scopus、CINAHL和谷歌学术在内的数据库以识别相关研究。符合条件的研究为随机对照试验,报告了脓毒性休克患者使用血管升压药和正性肌力药物的死亡率。我们选择将28天死亡率作为结局评估标准。
分析纳入了14项研究,共2811例患者。与多巴胺相比,去甲肾上腺素(NE)和NE+低剂量血管加压素而非肾上腺素(EPI)与死亡率显著降低相关。(优势比分别为0.80[95%可信区间,0.65 - 0.99]、0.69[0.48 - 0.98]和0.56[0.26 - 1.18])。与单独使用EPI或NE相比,添加多巴酚丁胺或多培沙明等正性肌力药物并未降低死亡率。
我们的结果支持在脓毒性休克中使用NE联合或不联合低剂量血管加压素作为一线血管升压治疗。没有确凿证据支持将EPI作为二线药物优于多巴胺或添加正性肌力药物。